BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29361818)

  • 1. Preclinical Study of Novel Curcumin Analogue SSC-5 Using Orthotopic Tumor Xenograft Model for Esophageal Squamous Cell Carcinoma.
    Tung LN; Song S; Chan KT; Choi MY; Lam HY; Chan CM; Chen Z; Wang HK; Leung HT; Law S; Huang Y; Song H; Lee NP
    Cancer Res Treat; 2018 Oct; 50(4):1362-1377. PubMed ID: 29361818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma.
    Mizumoto A; Ohashi S; Kamada M; Saito T; Nakai Y; Baba K; Hirohashi K; Mitani Y; Kikuchi O; Matsubara J; Yamada A; Takahashi T; Lee H; Okuno Y; Kanai M; Muto M
    J Gastroenterol; 2019 Aug; 54(8):687-698. PubMed ID: 30737573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periplcymarin targets glycolysis and mitochondrial oxidative phosphorylation of esophageal squamous cell carcinoma: Implication in anti-cancer therapy.
    Han L; Xiang X; Fu Y; Wei S; Zhang C; Li L; Liu Y; Lv H; Shan B; Zhao L
    Phytomedicine; 2024 Jun; 128():155539. PubMed ID: 38522311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma.
    Chu J; Niu X; Chang J; Shao M; Peng L; Xi Y; Lin A; Wang C; Cui Q; Luo Y; Fan W; Chen Y; Sun Y; Guo W; Tan W; Lin D; Wu C
    Theranostics; 2020; 10(8):3488-3502. PubMed ID: 32206103
    [No Abstract]   [Full Text] [Related]  

  • 5. The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma.
    Liu Y; Wang X; Zeng S; Zhang X; Zhao J; Zhang X; Chen X; Yang W; Yang Y; Dong Z; Zhu J; Xu X; Tian F
    J Exp Clin Cancer Res; 2018 Dec; 37(1):303. PubMed ID: 30518397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel carbazole sulfonamide microtubule-destabilizing agents exert potent antitumor activity against esophageal squamous cell carcinoma.
    Niu F; Liu Y; Jing Z; Han G; Sun L; Yan L; Zhou L; Wu Y; Xu Y; Hu L; Zhao X
    Cancer Lett; 2018 Apr; 420():60-71. PubMed ID: 29408653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrahydrocurcumin, Curcumin, and 5-Fluorouracil Effects on Human Esophageal Carcinoma Cells.
    Pendleton EG; Jamasbi RJ; Geusz ME
    Anticancer Agents Med Chem; 2019; 19(8):1012-1020. PubMed ID: 30652650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting integrin αvβ3 with indomethacin inhibits patient-derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma.
    Liu F; Wu Q; Han W; Laster K; Hu Y; Ma F; Chen H; Tian X; Qiao Y; Liu H; Kim DJ; Dong Z; Liu K
    Clin Transl Med; 2021 Oct; 11(10):e548. PubMed ID: 34709754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corilagin Inhibits Esophageal Squamous Cell Carcinoma by Inducing DNA Damage and Down-Regulation of RNF8.
    Qiu F; Liu L; Lin Y; Yang Z; Qiu F
    Anticancer Agents Med Chem; 2019; 19(8):1021-1028. PubMed ID: 30848215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pristimerin targeting NF-κB pathway inhibits proliferation, migration, and invasion in esophageal squamous cell carcinoma cells.
    Tu Y; Tan F; Zhou J; Pan J
    Cell Biochem Funct; 2018 Jun; 36(4):228-240. PubMed ID: 29781107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
    Bolidong D; Domoto T; Uehara M; Sabit H; Okumura T; Endo Y; Nakada M; Ninomiya I; Miyashita T; Wong RW; Minamoto T
    Sci Rep; 2020 Jul; 10(1):11807. PubMed ID: 32678196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice.
    Sugase T; Takahashi T; Serada S; Nakatsuka R; Fujimoto M; Ohkawara T; Hara H; Nishigaki T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Kishimoto T; Mori M; Doki Y; Naka T
    Int J Cancer; 2017 Jun; 140(11):2608-2621. PubMed ID: 28233302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scutellarin Suppresses Patient-Derived Xenograft Tumor Growth by Directly Targeting AKT in Esophageal Squamous Cell Carcinoma.
    Liu F; Zu X; Xie X; Zhang Y; Liu K; Chen H; Wang T; Bode AM; Dong Z; Kim DJ
    Cancer Prev Res (Phila); 2019 Dec; 12(12):849-860. PubMed ID: 31554627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment.
    Shi JJ; Xing H; Wang YX; Zhang X; Zhan QM; Geng MY; Ding J; Meng LH
    Cancer Lett; 2019 Sep; 459():145-155. PubMed ID: 31173854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma.
    Wang J; Zhang Z; Che Y; Yuan Z; Lu Z; Li Y; Wan J; Sun H; Chen Z; Pu J; He J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):469-481. PubMed ID: 29308536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Derived Xenograft and Mice Models in Esophageal Squamous Cell Carcinoma.
    Lam AK; Tang JC
    Methods Mol Biol; 2020; 2129():137-147. PubMed ID: 32056175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.
    Wang JN; Che Y; Yuan ZY; Lu ZL; Li Y; Zhang ZR; Li N; Li RD; Wan J; Sun HD; Sun N; Puno PT; He J
    Toxicol Appl Pharmacol; 2019 Feb; 365():71-83. PubMed ID: 30633885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
    Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
    Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HOX/PBX dimer formation as a potential therapeutic option in esophageal squamous cell carcinoma.
    Shen LY; Zhou T; Du YB; Shi Q; Chen KN
    Cancer Sci; 2019 May; 110(5):1735-1745. PubMed ID: 30844117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells.
    Liu T; Guan F; Wang Y; Zhang Z; Li Y; Cui Y; Li Z; Liu H; Zhang Y; Wang Y; Ma S
    Toxicol Appl Pharmacol; 2020 May; 395():114971. PubMed ID: 32217144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.